Rocuronium Fresenius rocuronium bromide 50mg/5mL solution for injection vial

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

rocuronium bromide, Quantity: 10 g/L

Disponible depuis:

Fresenius Kabi Australia Pty Ltd

DCI (Dénomination commune internationale):

Rocuronium bromide

forme pharmaceutique:

Injection, solution

Composition:

Excipient Ingredients: water for injections; glacial acetic acid; sodium acetate trihydrate; sodium chloride

Mode d'administration:

Intravenous

Unités en paquet:

10 x 5mL, 5 x 5mL

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

INDICATIONS,Rocuronium is indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation during routine induction, to provide muscle relaxation and to facilitate mechanical ventilation in adults, children and infants over 1 month of age.,Rocuronium is also indicated as an adjunct to general anaesthesia to facilitate endotracheal intubation during rapid sequence induction when suxamethonium is contraindicated, however, this has not been studied in infants and children.,Rocuronium is also indicated as an adjunct in the intensive care unit (ICU) to facilitate mechanical ventilation.

Descriptif du produit:

Visual Identification: A clear, colourless to pale brownish-yellow solution.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store at 2 to 8 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2014-11-12